Prevalence and clinical characteristics of COVID-19 in inpatients with schizophrenia in Wuhan, China

Table 2 Characteristics of schizophrenia patients with or without coronavirus disease 2019

	COVID-19 patients (n = 84)	Non-COVID-19 patients (n = 174)	F, Z or χ	P
Age (yr)	54.6 ± 9.5	51.1 ± 9.5	7.65	0.006
Gender (Male/ Female)	64/20 (76.2%/23.8%)	137/31 (78.7%/17.8%)	3.36	0.07
Marital status			1.06	0.59
Single	45/75 (60.0%)	104/160 (65.0%)
Married	9/75 (12.0%)	21/160 (13.1%)
Divorced	21/75 (28.0%)	35/160 (21.9%)
Weight (kg)	62.0 ± 10.3	67.8 ± 16.6	9.40	0.002
Blood pressure
Systolic pressure	122.5 ± 7.2	125.5 ± 8.0	7.98	0.005
Diastolic pressure	77.3 ± 5.7	76.6 ± 6.0	0.81	0.37
Smoker/non-smoker	11/65	92/74	35.8	0.000
Duration of illness (years)	29.4 ± 11.0	27.4 ± 10.3	2.09	0.14
Age of onset (years)	25.4 ± 7.9	23.8 ± 7.3	2.06	0.15
Comorbid physical diseases	43 (48.8%)	44/164 (26.8%)	11.9	0.001
Antipsychotics			14.1	0.03
Olanzapine	18 (21.4%)	16 (9.2%)
Risperidone	16 (19.0%)	45 (25.9%)
Clozapine	15 (17.9%)	55 (31.6%)
Quetiapine	13 (15.5%)	18 (10.3%)
Aripiprazole	11 (13.1%)	17 (9.8%)
Ziprasidone	4 (4.8%)	5 (2.9%)
Typicals	7 (8.3%)	18 (10.3%)
Antipsychotic dose (mg/d) (chlorpromazine equivalents)	264.4 ± 160.8	226.9 ± 152.8	3.16	0.08

COVID-19: Coronavirus disease 2019.